Amyotrophic Lateral Sclerosis (ALS)

Bach Pharma is currently developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's lead therapeutic, GVT®, has demonstrated synergistic effects in reversing neuroimmunodegeneration and mitochondrial dysfunction in multiple preclinical models.

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the United States and an estimated 450,000 people worldwide. ALS causes the progressive degeneration of motor neurons, resulting in rapidly advancing muscle weakness and atrophy that eventually leads to partial or total paralysis and death. The disease is fatal within just four years on average.

ALS is a debilitating fatal disease and patients have few options for treatment. Development of GVT® in this area may provide a significant benefit to ALS patients.